Axol Bioscience Ltd.’s Post

📣 We're launching our new product at SOT! 📣 We're excited to announce the launch of our new axoCells™ Atrial Cardiomyocyte kit, an all-in-one bundle to unlock iPSC technology for in vitro arrhythmia and cardiotoxicity research. And where better to launch it than at the Society of Toxicology 63rd Annual Meeting and ToxExpo? Key features of our Atrial Cardiomyocyte kit are: • Tailored culture medium and optimized coating solution for growth of the cells • Demonstrate chamber-specific pharmacological responses (see below) • No evidence of endogenous arrhythmia • Developed for use in advanced in vitro atrial fibrillation and cardiotoxicity models And with everything you need (including matched reagents) in one easy-to-use kit, you can save time and money, freeing you up to focus on the science and build better cardiac models for research and toxicity screening. Watch the video to hear more about this new product, and click here to learn about why we've developed this kit: https://hubs.la/Q02nY2tB0 If you're attending SOT then make sure to visit Booth #2032 to find out more. Looking to unlock iPSC technology for your cardiotoxicity models? Get in contact with us at:operations@axolbio.com Jan Turner Holly Rore, PhD Jamie Bhagwan #iPSCs #SOT #AtrialFibrillation #cardiotoxicity #StemCells